Research programme: orexin receptor antagonists - Johnson & Johnson

Drug Profile

Research programme: orexin receptor antagonists - Johnson & Johnson

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Johnson & Johnson
  • Class Small molecules
  • Mechanism of Action Orexin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Sleep disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Sleep-disorders in USA (SC, Injection)
  • 17 Nov 2010 Preclinical trials in Sleep disorders in USA (SC)
  • 17 Nov 2010 Preclinical pharmacodynamics data in Sleep disorders presented at the 40th Annual Meeting of the Society for Neuroscience (SFN-2010) ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top